ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,827.04
-1.54%
Dow Jones
41,938.45
-1.63%
US Dollar vs MXN
20.7185
0.00%
Brent Oil
79.285
0.00%
Bitcoin
94,656.34
-0.05%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Climb Bio Inc (CLYM) Cotización

Climb Bio Inc

Climb Bio Inc (CLYM)

NASDAQ
2.00
0.13
(6.95%)
Cerrado 11 Enero 3:00PM
Delayed by 15 minutes
2.00
-0.01
(-0.50%)
Fuera de horario: 6:35PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
2.00
Postura de Compra
2.01
Postura de Venta
2.23
Volume Operado de la Acción
1,706,374
1.97 Rango del Día 2.2669
1.73 Rango de 52 semanas 5.86
Capitalización de Mercado [m]
134.448M
Precio Anterior
1.87
Precio de Apertura
2.00
Hora
100
@
2
(formt)
Última hora de negociación
Volumen financiero
US$ 3,431,943
Precio Promedio Ponderado
2.0112
Volumen promedio (3 m)
331,015
Acciones en circulación
67,223,760
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-9.78
Beneficio por acción (BPA)
-0.52
turnover
-
Beneficio neto
-35.12M

Acerca de Climb Bio Inc

Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Companys lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cel... Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Companys lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
climbbio.com
Sede
Wilmington, Delaware, USA
Fundado
-
Climb Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CLYM. The last closing price for Climb Bio was US$1.87. Over the last year, Climb Bio shares have traded in a share price range of US$ 1.73 to US$ 5.86.

Climb Bio currently has 67,223,760 shares in issue. The market capitalisation of Climb Bio is US$125.71 million. Climb Bio has a price to earnings ratio (PE ratio) of -9.78.

CLYM Últimas noticias

Más noticias

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody...

09 Enero 2025
GlobeNewswire Inc.

Climb Bio to be Added to the Nasdaq Biotechnology Index

WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq:...

19 Diciembre 2024
GlobeNewswire Inc.

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team...

12 Noviembre 2024
GlobeNewswire Inc.

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors...

11 Noviembre 2024
GlobeNewswire Inc.

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences...

31 Octubre 2024
GlobeNewswire Inc.

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development...

15 Octubre 2024
GlobeNewswire Inc.

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take...

11 Octubre 2024
GlobeNewswire Inc.

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases...

04 Octubre 2024
GlobeNewswire Inc.

Climb Bio to Host Virtual Investor Event on October 15, 2024

WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of...

03 Octubre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.09-4.306220095692.092.361.872419172.18782505CS
4-0.9-31.03448275862.92.91.734560182.0596687CS
12-2.87-58.9322381934.875.11.733310152.963888CS
26-3.03-60.23856858855.035.861.733371043.35500845CS
52-3.03-60.23856858855.035.861.733371043.35500845CS
156-3.03-60.23856858855.035.861.733371043.35500845CS
260-3.03-60.23856858855.035.861.733371043.35500845CS

CLYM - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Climb Bio?
El precio actual de las acciones de Climb Bio es US$ 2.00
¿Cuántas acciones de Climb Bio están en circulación?
Climb Bio tiene 67,223,760 acciones en circulación
¿Cuál es la capitalización de mercado de Climb Bio?
La capitalización de mercado de Climb Bio es USD 125.71M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Climb Bio?
Climb Bio ha negociado en un rango de US$ 1.73 a US$ 5.86 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Climb Bio?
El ratio precio/beneficio de Climb Bio es -9.78
¿Cuál es la moneda de reporte de Climb Bio?
Climb Bio presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Climb Bio?
El último beneficio anual de Climb Bio es USD -35.12M
¿Cuál es la dirección registrada de Climb Bio?
La dirección registrada de Climb Bio es 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Climb Bio?
La dirección del sitio web de Climb Bio es climbbio.com
¿En qué sector industrial opera Climb Bio?
Climb Bio opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.7M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.69M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.56M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.16B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.45M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

Discusión

Ver feed completo
xxxx xxxx 4 minutos hace
u missed it
SHIBUSD
jour_trader jour_trader 4 minutos hace
I have plenty of experience with companies going through M&A as well, but not in the generic pharma market. How many generic pharma acquisitions have you been a part of? Industry means everything. I'd love nothing more than seeing a huge multiple. This is neither a tech stock or a company that has b
ELTP
Homebrew Homebrew 4 minutos hace
He needed victims to buy his shares. Same with the other long term pumpers.
...makes you wonder if he was in it from the start. ...
hap0206 hap0206 4 minutos hace
And we go to Indirect Subsidies to the oil/gas companies from the good ol americans -- per the environ fanatics -- such good folks
========
Indirect Subsidies

Last In, First Out Accounting (26 U.S. Code § 472. Active). The Last In, First Out accounting method (LIFO) allo
toohot toohot 5 minutos hace
This BIEL one from 3331:


WHICH CATALYST WILL BE FIRST?

1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/
BIEL QUBT
price_and_volume price_and_volume 5 minutos hace
Hello? Huggy been posting here ALSO since 2020...

In fact he was posting here PRIOR to TenKay, who started posting PRIOR to NoMoDo.

This is all neither here nor there of course, but why do you guys go off-topic to atack others and even THEN aren't particularly accurate
HMBL
StockItOut StockItOut 6 minutos hace
Duffy uses fake Nexboards all the time. Never uses real Nexboards as he and Xeriant have never produced Nexboard, evidenced by durever repeated fire testing that leads to durnever certification, nor actual production.
XERI
sodamnsane sodamnsane 6 minutos hace
It was likely a ploy to get investor information. Only thing you can do is pray they get what's coming to them or pay them a personal visit and show them what's coming. 
TSOI
12x 12x 6 minutos hace
Thank you for sharing your personal story about the AD trial.

The actual concern about high dropouts is poor drug tolerability, the bias risk, and the negative impact on the n. Regulators focus on those.

I completely agree. It's extremely challenging to bring a small-n
AVXL
janice shell janice shell 7 minutos hace
I think I would really have hated the Old West...
EmpressMonk25 EmpressMonk25 8 minutos hace
Is it only me, or can others also hear the wheels turning in TenKay and Huggies' heads?
HMBL
ubueltp ubueltp 8 minutos hace
That 8-12x is unrealisticly low for a growing company, in a growth market and a growing pipeline. To sell such a company, I would expect a minimum of 18x and as high as 25/26. I would expect this as I have significant experience in the selling and buying of companies. So, do your own DD and place yo
ELTP
joe_techi joe_techi 10 minutos hace
Great Harmonica. Always envied that capability
DKLN DKLN 12 minutos hace
Most likely nothing, That's why, after 6+ years, this stock sits at triple zeros with horrible volume and zippo revenue in the past 11 quarterly reports. Meanwhile, the kid generating revenue with his lemonade stand is working hard preparing some new flavored lemonade. BTW - The other two on this Bo
MCIC
Bubae Bubae 12 minutos hace
You were wrong to pump this stock and you are wrong to pump the other. The reasons I posted on the other board. You might try taking the conversation back over there. This isn't the place for it.
GRST
Involuntary-Recluse Involuntary-Recluse 14 minutos hace
https://investorshub.advfn.com/uimage/uploads/2025/1/11/fmybzToTheMoonTakingOffGIF.gif
CLHI
chrismiss_everyday chrismiss_everyday 14 minutos hace
Kudos to MayoMobile! 👏🧠🙌
AVXL
cottonmather cottonmather 16 minutos hace
Poplar Report. Ready or not Panama Canal , Greenland. 23 minutes https://youtu.be/beUO_EJKiAw?si=T2zIjs6TcOdnnbbe
Involuntary-Recluse Involuntary-Recluse 16 minutos hace
IMHO


FEAR= False Evidence Appearing Real ;-)

Better to REACT than to PREDICT 😂


Only Pinocchio 🤥 knows tomorrow for sure 😂 😂 😂


Carry on..
lowfloatmaster lowfloatmaster 16 minutos hace
Bro , come on.. 10.. u really think this company gunna get those contracts
I’m not buying it, and I own the stock
UMAV
lowfloatmaster lowfloatmaster 16 minutos hace
Bro , come on.. 10.. u really think this company gunna get those contracts
I’m not buying it, and I own the stock
UMAV
price_and_volume price_and_volume 16 minutos hace
What sort of DD is this?
NoMoDo, your involvement with the HUMBL ticker is clearly evident from your posting history well before the December surge. In contrast, TenKay only recently committed to the HUMBL ticker... a quick look indicates both gentlemen have been posting here pretty consisten
HMBL

Su Consulta Reciente

NASDAQ
CLYM
Climb Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados